Gastrointestinal Products Market Size Worth USD 25.85 Billion by 2034 | CAGR: 6.0%

The gastrointestinal products market size is expected to reach USD 25.85 billion by 2034, according to a new study by Polaris Market Research. The report “Gastrointestinal Products Market Size, Share, Trends, Industry Analysis Report: By Devices, Disease, End User (Hospitals, Ambulatory Centers and Independent Diagnostic Centers, Clinics, Other End Users), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS), are among the prevailing diseases driving the gastrointestinal products market growth. Since these conditions have become more common, there is a greater demand for effective treatments, prompting pharmaceutical companies to enhance their product offerings. Additionally, innovations in drug formulations and delivery systems have led to the development of therapies that are more effective and easier for patients to use, thereby improving compliance. This growing awareness of digestive health and the importance of early intervention further reinforces this trend, encouraging patients to seek timely treatment options led to insights.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/gastrointestinal-products-market/request-for-sample

Technological integration in healthcare, such as telemedicine platforms, electronic health records (EHRs), and mobile health applications, particularly through telemedicine and digital health technologies, is transforming the landscape of gastrointestinal care. These innovations enhance patient access to medical services, enabling remote consultations and effective management of gastrointestinal disorders. Patients are now able to receive timely diagnoses and ongoing support from healthcare professionals without the need for in-person visits, which is especially beneficial for those living in remote areas. Additionally, digital tools such as mobile health apps allow patients to monitor their symptoms, track dietary habits, and receive personalized treatment plans, promoting better health outcomes. Therefore, this shift has improved patient convenience, promoting a proactive approach to gastrointestinal health management and ultimately contributing to increased satisfaction and compliance.

Top of FormGastrointestinal Products Market Report Highlights

• In terms of disease, in 2024, gastroesophageal reflux disease (GERD) has emerged as the leading segment in the global gastrointestinal products market due to its widespread prevalence and growing public awareness.
• The ambulatory surgical centers (ASCs) segment is witnessing rapid growth in the gastrointestinal products market, driven by an increasing preference for outpatient procedures.
• In 2024, North America led the gastrointestinal products market, largely due to the prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and inflammatory bowel disease (IBD).
• Asia Pacific is projected to experience the fastest growth during the forecast period, driven by increasing healthcare spending, heightened awareness of gastrointestinal health, and a rising population grappling with lifestyle-related issues.
• A few global key market players include Abbott Laboratories; Johnson & Johnson; Pfizer Inc.; Bayer AG; Astellas Pharma Inc.; Takeda Pharmaceutical Company; Novartis International AG; GSK (GlaxoSmithKline); Mylan N.V.; Santen Pharmaceutical Co., Ltd.; Dr. Reddy’s Laboratories Ltd.

Polaris Market Research has segmented the gastrointestinal products market report on the basis of devices, disease, end user, and region:

By Devices Outlook (Revenue, USD Billion, 2020–2034)

• Endoscopy
  • Colonoscopy
  • Sigmoidoscopes
  • Capsule endoscopy systems
  • Other endoscopy devices/accessories
• Ablation system
  • Radiofrequency Ablation system
  • Microwave Ablation system
  • Cryoablation system  
  • Other ablation system
• Motility testing
  • Esophageal Manometry
  • 4-hour pH impedance testing
  • Anorectal Manometry
  • Other Motility testing
• Biopsy Devices
  • Needle Biopsy Devices
  • Endoscopic mucosal resection (EMR) devices
  • Endoscopic submucosal dissection (ESD) devices
  • Other Biopsy accessory products
• Stenting Devices
• pH monitoring devices
• Other gastroenterology devices

By Disease Outlook (Revenue, USD Billion, 2020–2034)

• Inflammatory Bowel Disease (IBD)
• Gastroesophageal reflux disease (GERD)
• Irritable bowel syndrome (IBS)
• Gastrointestinal cancer
• Other diseases

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Hospitals
• Ambulatory surgical centres and Independent diagnostic centres
• Clinics
• Other end users

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Gastrointestinal Products Report Scope